Skip to main content

Research Repository

Advanced Search

Antimicrobial peptides for leishmaniasis

Cobb, S.L.; Denny, P.W.

Antimicrobial peptides for leishmaniasis Thumbnail


Authors



Abstract

Leishmaniasis is a parasitic disease that is endemic to American, African, Asian and southern European countries. More than 350 million individuals in 88 countries are at risk of infection from this neglected tropical disease. No effective vaccinations are available against leishmaniasis, and control of the disease relies entirely on toxic drug treatments, some of which were developed as early as the 1940s. As parasite resistance becomes more prevalent, there is increasing concern that currently used drugs will soon become ineffective treatments. Consequently, an urgent need exists to develop new classes of compounds that are active against drug-resistant strains of Leishmania. This review summarizes research aimed at investigating the potential development of antimicrobial peptide-based antileishmanial agents.

Citation

Cobb, S., & Denny, P. (2010). Antimicrobial peptides for leishmaniasis. Current opinion in investigational drugs, 11(8), 868-875

Journal Article Type Article
Publication Date Aug 1, 2010
Deposit Date Aug 6, 2010
Publicly Available Date Mar 29, 2024
Journal Current opinion in investigational drugs.
Print ISSN 1472-4472
Electronic ISSN 2040-3429
Publisher Thomson Reuters
Peer Reviewed Peer Reviewed
Volume 11
Issue 8
Pages 868-875
Keywords AMP, Antileishmanial, Antimicrobial peptide, Drug resistance, Leishmania, Leishmaniasis, Therapy.
Publisher URL https://www.ncbi.nlm.nih.gov/labs/articles/20721829/

Files





You might also like



Downloadable Citations